# Photobiomodulation and Low-Level Laser Therapy as Complementary Strategies in Diabetes Treatment

**Authors:** Natalia Kurhaluk, Vladimir Tomin, Renata Kołodziejska, Halina Tkaczenko

PMC · DOI: 10.3390/ijms27042078 · International Journal of Molecular Sciences · 2026-02-23

## TL;DR

This review explores how laser therapies like photobiomodulation and low-level laser therapy may help treat diabetes complications by improving wound healing, pain, and metabolic control.

## Contribution

The paper highlights laser-based therapies as a novel complementary approach to conventional diabetes treatments.

## Key findings

- Laser therapy improves wound healing and alleviates neuropathic pain in diabetes.
- It enhances glycaemic control and modulates oxidative stress and inflammation.
- Laser therapy shows a favorable safety profile with minimal side effects.

## Abstract

Diabetes mellitus is a multifactorial metabolic disorder associated with a number of chronic complications, including neuropathy, impaired wound healing, vascular dysfunction, and metabolic dysregulation. Despite advances in pharmacological treatments and lifestyle interventions, current therapies often fail to prevent or reverse these complications entirely. This narrative review examines the therapeutic potential of laser-based modalities, particularly low-level laser therapy (LLLT) and photobiomodulation therapy (PBMT), as complementary strategies in diabetes management. Analysis of experimental and clinical studies shows that laser therapy can enhance wound healing, alleviate neuropathic pain, improve glycaemic control and insulin sensitivity, modulate inflammatory and oxidative stress pathways, and support vascular function. These effects are primarily mediated through mitochondrial activation, nitric oxide release, angiogenesis, modulation of redox-sensitive transcription factors, and preservation of pancreatic β-cell function. Furthermore, laser therapy exhibits a favourable safety profile with minimal side effects. The review highlights the current challenges, such as the lack of standardised treatment parameters (e.g., wavelength, dosage, and duration) and the limited number of large-scale clinical trials. It emphasises the need for personalised protocols and integration of laser therapy with pharmacological and physiotherapeutic interventions. Continued research and interdisciplinary collaboration are needed to realise the potential of laser therapy as an integral component of comprehensive, evidence-based diabetes care.

## Linked entities

- **Diseases:** diabetes mellitus (MONDO:0005015), neuropathy (MONDO:0005244)

## Full-text entities

- **Genes:** AKR1B1 (aldo-keto reductase family 1 member B) [NCBI Gene 231] {aka ADR, ALDR1, ALR2, AR}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, CCL17 (C-C motif chemokine ligand 17) [NCBI Gene 6361] {aka A-152E5.3, ABCD-2, SCYA17, TARC}, SGCB (sarcoglycan beta) [NCBI Gene 6443] {aka A3b, LGMD2E, LGMDR4, SGC}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 6346] {aka I-309, P500, SCYA1, SISe, TCA3}, PRKG1 (protein kinase cGMP-dependent 1) [NCBI Gene 5592] {aka AAT8, PKG, PKG1, PRKG1B, PRKGR1B, cGK}, IARS1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 3376] {aka GRIDHH, IARS, ILERS, ILRS, IRS, PRO0785}, CAT (catalase) [NCBI Gene 847], INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GAD1 (glutamate decarboxylase 1) [NCBI Gene 2571] {aka CPSQ1, DEE89, GAD, GAD-67, SCP}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}
- **Diseases:** phototoxicity (MESH:D017484), autoimmune (MESH:D001327), neuropathic (MESH:D009437), GDM (MESH:D016640), musculoskeletal pain (MESH:D059352), obesity (MESH:D009765), bleeding (MESH:D006470), chronic pain (MESH:D059350), hypoxic (MESH:D002534), adipose tissue dysfunction (MESH:D018205), nephropathy (MESH:D007674), neonatal hypoglycaemia (MESH:D007232), fatty liver disease (MESH:D005234), MODY (MESH:D003924), musculoskeletal conditions (MESH:D009140), LLLT (MESH:D009800), Hypercoagulation (MESH:D019851), Type 1 diabetes mellitus (MESH:D003922), energy (MESH:D011502), systemic (MESH:D015619), stroke (MESH:D020521), DKA (MESH:D016883), retinopathy (MESH:D058437), retinal damage (MESH:D012164), fatigue (MESH:D005221), polyphagia (MESH:D006963), paresthesia (MESH:D010292), DPN (MESH:D010523), diabetic angiopathies (MESH:D003925), beta-cell dysfunction (MESH:D007340), latent autoimmune diabetes in (MESH:D000071698), spinal cord injury (MESH:D013119), erythema (MESH:D004890), acne (MESH:D000152), Chronic foot ulcers (MESH:D016523), maternal and (MESH:D000079262), psoriasis (MESH:D011565), Cushing's syndrome (MESH:D003480), necrosis (MESH:D009336), periodontal disease (MESH:D010510), cardiotoxicity (MESH:D066126), ischaemia (MESH:D007511), atherosclerotic plaque (MESH:D058226), metabolic dysregulation (MESH:D021081), vascular and neurological dysfunctions (MESH:D009461), osteoarthritis (MESH:D010003), Metabolic Diseases (MESH:D008659), seizures (MESH:D012640), vascular fragility (MESH:D005600), pancreatic disease (MESH:D010182), burns (MESH:D002056), chronic (MESH:D002908), neck pain (MESH:D019547), hypoxia (MESH:D000860), cognitive impairment (MESH:D003072), lupus vulgaris (MESH:D008177), neuropathy (MESH:D009422), maturity-onset diabetes of the young (MESH:C562772), blindness (MESH:D001766), chronic low back pain (MESH:D017116)
- **Chemicals:** GSH (MESH:D005978), CO2 (MESH:D002245), FMN (MESH:D005486), fructose (MESH:D005632), Sorbitol (MESH:D013012), water (MESH:D014867), ATP (MESH:D000255), phospholipid (MESH:D010743), AGEs (MESH:D017127), coenzyme Q (MESH:D014451), lipid (MESH:D008055), glycogen (MESH:D006003), copper (MESH:D003300), RNS (MESH:D011886), heparin (MESH:D006493), acetate (MESH:D000085), NAD+ (MESH:D009243), thromboxane B2 (MESH:D013929), blood glucose (MESH:D001786), hexosamine (MESH:D006595), calcium (MESH:D002118), cyclic AMP (MESH:D000242), aldehyde (MESH:D000447), FADH2 (MESH:C058805), ROS (MESH:D017382), glucose (MESH:D005947), C-peptide (MESH:D002096), NO (MESH:D009569), bevacizumab (MESH:D000068258), histamine (MESH:D006632), LED (-), GTP (MESH:D006160), cGMP (MESH:D006152), oxygen (MESH:D010100), doxorubicin (MESH:D004317), NADPH (MESH:D009249), prostaglandins (MESH:D011453), reactive nitrogen species (MESH:D026361), BH4 (MESH:C003402), ranibizumab (MESH:D000069579), PIP2 (MESH:D019269), haem (MESH:D006418), omega-3 fatty acids (MESH:D015525), polyol (MESH:C024617), peroxide (MESH:D010545), phosphatidylinositol 3,4,5-trisphosphate (MESH:C060974), carbohydrate (MESH:D002241), triacylglycerol (MESH:D014280), ADP (MESH:D000244), FAD (MESH:D005182)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940873/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940873/full.md

## References

291 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940873/full.md

---
Source: https://tomesphere.com/paper/PMC12940873